Safety and efficacy of bexarotene in patients with relapsing-remitting multiple sclerosis (CCMR One): a randomised, double-blind, placebo-controlled, parallel-group, phase 2a study. (2021)
Attributed to:
UK Dementias Platform
funded by
MRC
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.17863/cam.70696
Publication URI: https://www.repository.cam.ac.uk/handle/1810/323242
Type: Journal Article/Review